{"id":"hr17031-injection","safety":{"commonSideEffects":[{"rate":null,"effect":"Hypertension"},{"rate":null,"effect":"Proteinuria"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Diarrhea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"HR17031 functions as a VEGF pathway inhibitor, blocking the formation of new blood vessels that tumors depend on for growth and metastasis. By targeting VEGF receptors, the drug starves tumors of their blood supply, thereby inhibiting tumor progression. This anti-angiogenic mechanism is commonly employed in oncology to reduce tumor vascularization and improve therapeutic outcomes.","oneSentence":"HR17031 is an anti-angiogenic agent that inhibits vascular endothelial growth factor (VEGF) signaling to suppress tumor blood vessel formation.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T00:45:38.064Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Solid tumors (specific indications under investigation in phase 3)"}]},"trialDetails":[{"nctId":"NCT06881264","phase":"PHASE3","title":"A Study Comparing HR17031 With Insulin Glargine in Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2024-04-30","conditions":"Adult Patients With Type 2 Diabetes Uncontrolled on Oral Antidiabetic Drugs","enrollment":401},{"nctId":"NCT06871761","phase":"PHASE3","title":"A Trial Comparing HR17031 With Insulin Glargine in Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2024-05-08","conditions":"Adult Patients With Type 2 Diabetes","enrollment":393},{"nctId":"NCT06086912","phase":"PHASE1","title":"A Clinical Study to Compare the Bioavailability of HR17031 in Healthy Subjects at Different Sites","status":"COMPLETED","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2023-11-07","conditions":"Type 2 Diabetes","enrollment":24},{"nctId":"NCT05333835","phase":"PHASE2","title":"A Trial Comparing the Efficacy and Safety of HR17031 Injection to INS068 Injection and to SHR20004 Injection in Patients With Type 2 Diabetes","status":"UNKNOWN","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2022-07-08","conditions":"Type 2 Diabetes","enrollment":455},{"nctId":"NCT05031871","phase":"PHASE1","title":"Pharmacokinetics of HR17031 Injection in Healthy Subjects","status":"COMPLETED","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2021-09-02","conditions":"Type 2 Diabetes Mellitus","enrollment":24},{"nctId":"NCT05292495","phase":"PHASE1","title":"A Trial of HR17031 Injection With Renal Insufficiency","status":"UNKNOWN","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2022-03-31","conditions":"Improved Glycemic Control in Patients With Type 2 Diabetes","enrollment":48},{"nctId":"NCT05151705","phase":"PHASE1","title":"A Trial of HR17031 Injection With Hepatic Insufficiency","status":"UNKNOWN","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2021-12-20","conditions":"Improved Glycemic Control in Patients With Type 2 Diabetes","enrollment":24}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"HR17031 injection","genericName":"HR17031 injection","companyName":"Jiangsu HengRui Medicine Co., Ltd.","companyId":"jiangsu-hengrui-medicine-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"HR17031 is an anti-angiogenic agent that inhibits vascular endothelial growth factor (VEGF) signaling to suppress tumor blood vessel formation. Used for Solid tumors (specific indications under investigation in phase 3).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}